Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
Globenewswire·2025-07-21 07:30
ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Approval is based on positive results from the pivotal Phase III ARANOTE trial.This broadened indication allows doctors to use darolutamide plus ADT, with or without chemothera ...